Vaccine Sales Hurt by Weak Flu Season Last Year: Kalorama
(firmenpresse) - NEW YORK, NY -- (Marketwire) -- 09/27/12 -- For the first time in a decade, sales of vaccines declined, according to Kalorama Information. The notes that a weak flu season last year which resulted in a decline in influenza sales, along with some other product changes, led to a 30% decline in the market to $19.8 billion in 2011, down from $24.1 billion in 2010. However, Kalorama projects that the world vaccines market will quickly rebound -- increasing at a compound annual rate of 8.9% during 2011-2016, as forecasted in its report: .
"What goes up must come down and so it is with ," said Bruce Carlson, publisher of Kalorama Information. "We should be clear that our estimate reflects overall vaccine sales, and these results mostly have to do with and a few other categories and do not change the overall trend that pharmaceutical companies are heavily interested in as part of their growth strategies."
The report said that while sales of adult influenza vaccines had been strong in 2009 and 2010 due to government stockpiling -- and in some cases, over-purchasing -- of new avian and swine flu vaccines, sales have since returned to earlier, pre-pandemic levels. All of the major manufacturers reported significant declines from 2010.
The severity of flu seasons can vary significantly from year to year. In May 2012, the CDC announced in its FluView report that the 2011-2012 flu season had been mild, beginning late across most of the United States. Influenza in the United States typically starts to increase in late December or early January and peaks in February. This past season, flu remained low through February and did not reach baseline until mid-March, never exceeding baseline during the season.
Kalorama Information details 14 segments of vaccines in its yearly market research report on vaccine sales. According to the report, the majority of these categories grew last year and will continue to show positive growth rates.
"There are several areas of vaccines that have bucked the overall market trend and increased in 2011, and we detail these in our report," Carlson said. "There is also a considerable amount of R&D in vaccines, which we detail as well."
Kalorama Information's contains a complete overview of the vaccine market in 14 segments, includes profiles and competitive analysis of the key players, and a discussion of issues and trends facing the industry.
Kalorama Information, a division of MarketResearch.com, supplies the latest in independent in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on , and our .
Please direct all media inquiries to:
Bruce Carlson
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 27.09.2012 - 16:29 Uhr
Sprache: Deutsch
News-ID 187515
Anzahl Zeichen: 6803
contact information:
Town:
NEW YORK, NY
Kategorie:
Hospitals, Facilities and Providers
Diese Pressemitteilung wurde bisher 243 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Vaccine Sales Hurt by Weak Flu Season Last Year: Kalorama"
steht unter der journalistisch-redaktionellen Verantwortung von
Kalorama Information (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
